SCHEMBL5947560

SCHEMBL5947560

FC(F)(F)c1cccc(CCNCc2cccc(Oc3cccc4ccccc34)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.51
▸ ROCK1 Q13464 1/20 0.51
▸ HTT P42858 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ SLC6A2 P23975 3/20 0.46
▸ SLC6A4 P31645 3/20 0.46
▸ ADRA2C P18825 2/20 0.46
▸ HTR2C P28335 2/20 0.46
▸ OPRM1 P35372 2/20 0.46
▸ DRD3 P35462 2/20 0.46
▸ CASR P41180 2/20 0.46
▸ MLNR O43193 1/20 0.46
▸ ABCB11 O95342 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947686 0.87 KDM4E (0.60) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947565 0.85 KDM4E (0.61) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947704 0.85 KDM4E (0.69) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947401 0.83 CYP1A2 (0.52) KMT2ACYP2D6HTR2ABCHESMPD1
SCHEMBL5947469 0.82 KDM4E (0.62) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947369 0.81 KDM4E (0.64) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947251 0.79 KDM4E (0.61) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL27595872 0.79 ROCK1 (0.53) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947464 0.78 BCHE (0.74) KDM4EKMT2AMEN1TDP1ROCK1
SCHEMBL5947177 0.78 KDM4E (0.58) KDM4EKMT2AMEN1TDP1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KDM4E 1970/4885KMT2A 1269/4885MEN1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback